Retinopathy of prematurity in the Republic of Belarus: a ten-year epidemiological analysis and its impact on screening
https://doi.org/10.65249/1027-7218-2025-12-15-22
Abstract
Objective. To analyze the dynamics of epidemiological indicators of retinopathy of prematurity (ROP) in the Republic of Belarus from 2014 to 2024 and to determine its place within the structure of pediatric ophthalmopathology and surgical activity.
Material and methods. A retrospective analysis of statistical data on ROP was conducted based on reports from freelance pediatric ophthalmology specialists and data from the State Institution “Republican Scientific and Practical Center 'Mother and Child'” (RSPC “Mother and Child”) for the period 2014–2024. Indicators analyzed included rates of preterm birth, distribution of newborns by birth weight (BW) (< 2000 g, < 1500 g, and < 1000 g), incidence of ROP, structure of disease stages, and volume of performed ophthalmic surgeries. The statistical significance of trends was assessed using linear regression (r), χ² test, and Student's t-test (p < 0.05).
Results. It was found that the average annual rate of preterm births was 3.9% (3335 ± 152 cases), and the proportion of children with BW < 1500 g increased from 6.8 % to 9.4 % (r = 0.92, p < 0.001). Retinopathy of prematurity was diagnosed in 7,022 (22.4%) preterm infants according to the RSPC “Mother and Child” data, which corresponds to 1.5% of all pediatric ophthalmopathology and is comparable to congenital eye anomalies (1.7 %). Over 11 years, the proportion of end-stage ROP declined from 2.0 % to 0.8 %, and ROP surgery consistently accounted for 10 % of all pediatric ophthalmic procedures (second most common in patients < 1 year).
Conclusion. ROP remains a major cause of childhood visual disability; growth of the extremely-low-birth-weight cohort necessitates refinement of risk-stratified screening. These data provide an epidemiologic basis for revising national eligibility criteria and follow-up schedules for infants at high risk of ROP.
About the Authors
V. KrasilnikovaБеларусь
O. Dudich
Беларусь
I. Smirnov
Беларусь
References
1. Kim S.J., Port A.D., Swan R. Retinopathy of prematurity. Surv Ophthalmol. 2018; 63: 618–637.
2. Nair A., Ballushi R.El., Anklesaria B.Z., et al. Review on the incidence and related risk factors of retinopathy of prematurity across various countries. Cureus. 2022; 14(11). doi: 10.7759/cureus.32007.
3. Wilkinson A.R., Adams G.G.W., Fleck B.W., Nieto-Hernandez R. UK screening and treatment of retinopathy of prematurity. Early Hum Dev. 2023; 177–178. doi: 10.1016/j.earlhumdev.2023.105715.
4. Batais W.T., Taher N.O., Alhindi A.K., et al. Efficacy and safety of prophylactic agents in prevention of retinopathy of prematurity. BMJ Open Ophthalmol. 2024; 9(1). doi: 10.1136/bmjophth-2024-001910.
5. Bishnoi K., Prasad R., Upadhyay T., Mathurkar S. A. Narrative review on managing retinopathy of prematurity: insights into pathogenesis, screening, and treatment strategies. Cureus. 2024; 16(3): doi: 10.7759/cureus.56168.
6. Kıran Yenice E., Kara C., Karsli Turkoglu T., Ulubas Isık D., et al. Predictive value of serum inflammatory markers in retinopathy of prematurity. Eye (London). 2024; 38(14): 2822–2826.
7. Strube Y.N.J., Wright K.W. Pathophysiology of retinopathy of prematurity // Saudi J Ophthalmol. 2022; 36(3): 239–246.
8. Simchanka A.V., Ulezko E.A., Mankevich N.A., et al. Retinopathy of prematurity in children: early detection, monitoring, analysis. Ohrana materinstva i detstva. 2024; 1(143): 58–61.
9. Suelves A.M., Shulman J.P. Current screening and treatments in retinopathy of prematurity in the US. Eye Brain. 2016; 8: 37–43.
10. Wilkinson A.R., Haines L., Head K., Fielder A.R. UK retinopathy of prematurity guideline. Eye. 2009; 23(11): 2137–2139.
11. Wood E.H., Chang E.Y., Beck K., et al. 80 years of vision: preventing blindness from retinopathy of prematurity. J Perinatol. 2021; 41(6): 1216–1224.
Review
For citations:
Krasilnikova V., Dudich O., Smirnov I. Retinopathy of prematurity in the Republic of Belarus: a ten-year epidemiological analysis and its impact on screening. Healthcare. 2025;(12):15-22. (In Russ.) https://doi.org/10.65249/1027-7218-2025-12-15-22
JATS XML
